NI
AIMT

Numeric Investors’s Aimmune Therapeutics AIMT Stock Holding History

Numeric Investors’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-34,800
Closed -$642K – 1178
2015
Q4 		$642K Buy
+34,800
New +$644K 0.01% 673

Other funds holding AIMT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
TG
TLP Group Evanston, Illinois $6.61M AUM 12.46% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return

Numeric Investors's AIMT Position: Q1 2016 in Review

Numeric Investors sold out of Aimmune Therapeutics (AIMT) in Q1 2016, closing a stake of 34,800 shares — an estimated $642K sold.

Numeric Investors first reported a position in AIMT in Q4 2015 and held it in 1 quarter. The position peaked at $642K in Q4 2015. 69 funds tracked by Wall St. Rank hold AIMT as of Q1 2016.

  • Numeric Investors reported no remaining Aimmune Therapeutics position as of Q1 2016 after selling out during the quarter.
  • Numeric Investors sold 34,800 Aimmune Therapeutics shares in Q1 2016, an estimated $642K.
  • Numeric Investors first reported a position in Aimmune Therapeutics in Q4 2015 and held it in 1 quarter.
  • Numeric Investors's Aimmune Therapeutics position peaked at $642K in Q4 2015.
  • 69 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q1 2016.

Based on Numeric Investors's 13F filing for Q1 2016, filed 6 May 2016.